{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T22:59:35Z","timestamp":1775429975552,"version":"3.50.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1038\/s41440-025-02521-4","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T03:39:18Z","timestamp":1767843558000},"page":"1523-1526","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Positioning esaxerenone, a non-steroidal mineralocorticoid receptor antagonist, in the treatment of hypertension with and without hemodynamic cardiac stress"],"prefix":"10.1038","volume":"49","author":[{"given":"Yoshitaka","family":"Gunji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasutomi","family":"Higashikuni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masataka","family":"Sata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"2521_CR1","first-page":"e895","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e895\u2013e1032.","journal-title":"Circulation"},{"key":"2521_CR2","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1038\/s41440-025-02331-8","volume":"48","author":"Y Ohya","year":"2025","unstructured":"Ohya Y, Sakima A, Arima H, Fukami A, Furuhashi M, Ishida M, et al. Key highlights of the Japanese Society of Hypertension Guidelines for the management of elevated blood pressure and hypertension 2025 (JSH2025). Hypertens Res. 2025;48:2500\u201311.","journal-title":"Hypertens Res"},{"key":"2521_CR3","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1002\/ejhf.319","volume":"17","author":"H Shimokawa","year":"2015","unstructured":"Shimokawa H, Miura M, Nochioka K, Sakata Y. Heart failure as a general pandemic in Asia. Eur J Heart Fail. 2015;17:884\u201392.","journal-title":"Eur J Heart Fail"},{"key":"2521_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2025.102637","volume":"13","author":"JL Harrington","year":"2025","unstructured":"Harrington JL, Canonico ME, El Rafei A, Solomon SD, Teerlink JR, Vaduganathan M, et al. Nonsteroidal and steroidal mineralocorticoid antagonists: rationale, evidence, and unanswered questions. JACC Heart Fail. 2025;13:102637.","journal-title":"JACC Heart Fail"},{"key":"2521_CR5","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1093\/eurheartj\/ehac299","volume":"43","author":"AK Pandey","year":"2022","unstructured":"Pandey AK, Bhatt DL, Cosentino F, Marx N, Rotstein O, Pitt B, et al. Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. Eur Heart J. 2022;43:2931\u201345.","journal-title":"Eur Heart J"},{"key":"2521_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/clc.70137","volume":"48","author":"T Naruke","year":"2025","unstructured":"Naruke T, Hashimura-Kakogawa M, Suzuki Y, Ikeda Y, Kitasato L, Nabeta T, et al. The role of esaxerenone in the continuum of heart failure with preserved ejection fraction: insights from a prospective observational study. Clin Cardiol. 2025;48:e70137.","journal-title":"Clin Cardiol"},{"key":"2521_CR7","doi-asserted-by":"publisher","unstructured":"Kario K, Ohishi M, Katsuya T, Shimosawa T, Shiosakai K, Furugori T, et al. Effect of N-terminal pro B-type natriuretic peptide levels on the efficacy and safety of esaxerenone vs trichlormethiazide for the treatment of Japanese patients with uncontrolled essential hypertension: a subanalysis of the EXCITE-HT study. Hypertens Res. https:\/\/doi.org\/10.1038\/s41440-025-02412-8.","DOI":"10.1038\/s41440-025-02412-8"},{"key":"2521_CR8","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1038\/s41440-024-01762-z","volume":"47","author":"K Kario","year":"2024","unstructured":"Kario K, Ohbayashi H, Hashimoto M, Itabashi N, Kato M, Uchiyama K, et al. Home blood pressure-lowering effect of a non-steroidal mineralocorticoid receptor blocker, esaxerenone, versus trichlormethiazide for uncontrolled hypertension: the EXCITE-HT randomized controlled study. Hypertens Res. 2024;47:2435\u201346.","journal-title":"Hypertens Res"},{"key":"2521_CR9","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.122.060860","volume":"147","author":"Y Higashikuni","year":"2023","unstructured":"Higashikuni Y, Liu W, Numata G, Tanaka K, Fukuda D, Tanaka Y, et al. NLRP3 inflammasome activation through heart-brain interaction initiates cardiac inflammation and hypertrophy during pressure overload. Circulation. 2023;147:338\u201355.","journal-title":"Circulation"},{"key":"2521_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejim.2020.07.006","volume":"80","author":"C Borghi","year":"2020","unstructured":"Borghi C, Agabiti-Rosei E, Johnson RJ, Kielstein JT, Lurbe E, Mancia G, et al. Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease. Eur J Intern Med. 2020;80:1\u201311.","journal-title":"Eur J Intern Med"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02521-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02521-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02521-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T22:14:07Z","timestamp":1775427247000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02521-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2521"],"URL":"https:\/\/doi.org\/10.1038\/s41440-025-02521-4","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"assertion":[{"value":"18 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"MS has received speaking honoraria from Mochida Pharmaceutical Co., Ltd., Novartis AG, Novo Nordisk Pharma, Ltd., and\u00a0Daiichi Sankyo Company, Ltd. The other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}